Alvotech Ordinary Shares (ALVO) Dividend History

Company News

• Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

  Alvotech and Dr. Reddy's have entered into a collaboration to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets.

  GlobeNewswire Inc.
• Alvotech og Dr. Reddys ganga til samstarfs um þróun hliðstæðu við krabbameinslyfið Keytruda

  Alvotech, a biotech company, has entered into a collaboration with Dr. Reddy's Laboratories, an Indian pharmaceutical company, to co-develop a biosimilar version of the cancer drug Keytruda. The collaboration aims to reduce development and manufacturing costs, shorten the development timeline, and accelerate global market access for the biosimilar.

  GlobeNewswire Inc.
• Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

  Alvotech and Dr. Reddy's have entered into a collaboration to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets.

  GlobeNewswire Inc.
• Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

  Alvotech has completed a private placement of 7,500,000 SDRs and ordinary shares, raising gross proceeds of SEK 750 million. The proceeds will be used for R&D expansion, growth opportunities, and general corporate purposes.

  GlobeNewswire Inc.
• Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna

  Alvotech, a biotech company, has completed a private placement of 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares, raising 750 million Swedish Krona. The placement was well-received by institutional investors, primarily from Sweden and other international markets.

  GlobeNewswire Inc.